Medical devices, healthcare technology and the business of care
510(k) clearance · K261321

Yomi S Robotic System

Neocis, Inc. · Decision date Oct 13, 2026

MEDTECHLEDGER EXPLANATIONK261321

What did the FDA decide?

The FDA's 510(k) final decision list records K261321 for the Yomi S Robotic System, submitted by Neocis, Inc., with a decision of substantially equivalent (SESE) and a published date of 13 October 2026. The record places the device in the dental specialty under product code QRY. Substantial equivalence is a 510(k) clearance, not a premarket approval of the device.

The source identifies the applicant and device name but does not describe the specific components, design changes or indications covered by this submission, nor does it state a predicate device or the basis for the equivalence finding. Those details would sit in the underlying 510(k) review documents rather than the decision listing. The same listing also carries unrelated clearances, including K261572 and K252288, which are separate submissions and not part of this record.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Dental
Decision date
Oct 13, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261321
Regulatory pathway
510(k) premarket notification
Applicant
Neocis, Inc.
Product code
QRY
Decision code
SESE
Decision date
Oct 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dental Navigation System.

Applicant
Neocis, Inc.
Product code
QRY
FDA device class
2

FDA decision timeline

  1. K261321 received

    Application receipt date recorded by FDA.

  2. K261321 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neocis, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Miami, FL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records